Feedback control through cGMP-dependent protein kinase contributes to differential regulation and compartmentation of cGMP in rat cardiac myocytes

Circulation Research

Volumn 107, Issue 10, 2010, Pages 1232-1240

  Castro, Liliana R V ^a   Schittl, Julia ^a   Fischmeister, Rodolphe ^a  

^a INSERM   (France)

Author keywords

cGMP; cGMP dependent protein kinase; natriuretic peptides; nitric oxide; phosphodiesterase type 5

Indexed keywords

CYCLIC GMP; CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIC GMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC GMP PHOSPHODIESTERASE; CYCLIC NUCLEOTIDE GATED CHANNEL; DT 2; GUANYLATE CYCLASE; ISOBUTYLMETHYLXANTHINE; KT 5823; N ACETYL S NITROSOPENICILLAMINE; PARTICULATE CYCLASE; PHOSPHODIESTERASE V; SILDENAFIL; SOLUBLE GUANYLYL CYCLASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL COMPARTMENTALIZATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART MUSCLE CELL; NEGATIVE FEEDBACK; NONHUMAN; POSITIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

EID: 78549296353     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.110.226712     Document Type: Article

References (59)

1. Potter LR, Abbey-Hosch S, Dickey DM. Natriuretic peptides, theirreceptors and cyclic guanosine monophosphate-dependent signalingfunctions. Endocr Rev. 2006;27:47-72.
2. Pyriochou A, Papapetropoulos A. Soluble guanylyl cyclase: more secretsrevealed. Cell Signal. 2005;17:407-443.
3. Hofmann F, Feil R, Kleppisch T, Schlossmann J. Function of cGMPdependentprotein kinases as revealed by gene deletion. Physiol Rev.2006;86:1-23.
4. Méry P-F, Lohmann SM, Walter U, Fischmeister R. Ca2- current isregulated by cyclic GMP-dependent protein kinase in mammalian cardiacmyocytes. Proc Natl Acad Sci USA. 1991;88:1197-1201.
5. Schroder F, Klein G, Fiedler B, Bastein M, Schnasse N, Hillmer A, AmesS, Gambaryan S, Drexler H, Walter U, Lohmann SM, Wollert KC. SingleL-type Ca2- channel regulation by cGMP-dependent protein kinase typeI in adult cardiomyocytes from PKG I transgenic mice. Cardiovasc Res.2003;60:268-277.
6. Raeymaekers L, Hofmann F, Casteels R. Cyclic GMP-dependent proteinkinase phosphorylates phospholamban in isolated sarcoplasmic reticulumfrom cardiac and smooth muscle. Biochem J. 1988;252:269-273.
7. Blimenthal DK, Stull JT, Gill GN. Phosphorylation of cardiac troponin byguanosine 3-:5-monophosphate-dependent protein kinase. J Biol Chem.1978;253:334-336.
8. Lincoln TM, Corbin JD. Purified cyclic GMP-dependent protein kinasecatalyzes the phosphorylation of cardiac troponin inhibitory subunit(TN-I). J Biol Chem. 1978;253:337-339.
9. Tsai EJ, Kass DA. Cyclic GMP signaling in cardiovascular pathophysiologyand therapeutics. Pharmacol Ther. 2009;122:216-238.
10. Méry P-F, Pavoine C, Belhassen L, Pecker F, Fischmeister R. Nitric oxideregulates cardiac Ca2- current. Involvement of cGMP-inhibited andcGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem. 1993;268:26286-26295.
11. Gisbert M-P, Fischmeister R. Atrial natriuretic factor regulates thecalcium current in frog isolated cardiac cells. Circ Res. 1988;62:660-667.
12. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, KetnerEA, Moens AL, Champion HC, Kass DA. Compartmentalization ofcardiac-adrenergic inotropy modulation by phosphodiesterase type.5. Circulation. 2007;115:2159-2167.
13. Su J, Scholz PM, Weiss HR. Differential effects of cGMP produced bysoluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp Biol Med (Maywood). 2005;230:242-250.
14. Rho EH, Perkins WJ, Lorenz RR, Warner DO, Jones KA. Differentialeffects of soluble and particulate guanylyl cyclase on Ca2- sensitivity inairway smooth muscle. J Appl Physiol. 2002;92:257-263.
15. Wen JF, Cui X, Jin JY, Kim SM, Kim SZ, Kim SH, Lee HS, Cho KW.High and low gain switches for regulation of cAMP efflux concentration:distinct roles for particulate GC-and soluble GC-cGMP-PDE3 signalingin rabbit atria. Circ Res. 2004;94:936-943.
16. Castro LRV, Verde I, Cooper DMF, Fischmeister R. Cyclic guanosinemonophosphate compartmentation in rat cardiac myocytes. Circulation.2006;113:2221-2228.
17. Fischmeister R, Castro LRV, Abi-Gerges A, Rochais F, Jurevic?ius J, Leroy J, Vandecasteele G. Compartmentation of cyclic nucleotide signalingin the heart. The role of cyclic nucleotide phosphodiesterases. CircRes. 2006;99:816-828.
18. Rochais F, Vandecasteele G, Lefebvre F, Lugnier C, Lum H, Mazet J-L, Cooper DMF, Fischmeister R. Negative feedback exerted by PKA andcAMP phosphodiesterase on subsarcolemmal cAMP signals in intactcardiac myocytes. An in vivo study using adenovirus-mediated expressionof CNG channels. J Biol Chem. 2004;279:52095-52105.
19. Murthy KS. Activation of phosphodiesterase 5 and inhibition of guanylatecyclase by cGMP-dependent protein kinase in smooth muscle. Biochem J.2001;360:199-208.
20. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylylcyclase. Circ Res. 2003;93:96-105.
21. Corbin JD, Turko IV, Beasley A, Francis SH. Phosphorylation ofphosphodiesterase-5 by cyclic nucleotide-dependent protein kinase altersits catalytic and allosteric cGMP-binding activities. Eur J Biochem. 2000;267:2760-2767.
22. Kaupp UB, Seifert R. Cyclic nucleotide-gated ion channels. Physiol Rev.2002;82:769-824.
23. Komalavilas P, Lincoln TM. Phosphorylation of the inositol 1, 4, 5-trisphosphate receptor. Cyclic GMP-dependent protein kinase mediatescAMP and cGMP dependent phosphorylation in the intact rat aorta. J BiolChem. 1996;271:21933-21938.
24. Dostmann WR, Taylor MS, Nickl CK, Brayden JE, Frank R, Tegge WJ.Highly specific, membrane-permeant peptide blockers of cGMPdependentprotein kinase Ialpha inhibit NO-induced cerebral dilation. Proc Natl Acad Sci USA. 2000;97:14772-14777.
25. Burkhardt M, Glazova M, Gambaryan S, Vollkommer T, Butt E, Bader B, Heermeier K, Lincoln TM, Walter U, Palmetshofer A. KT5823 inhibitscGMP-dependent protein kinase activity in vitro but not in intact humanplatelets and rat mesangial cells. J Biol Chem. 2000;275:33536-33541.
26. Bain J, McLauchlan H, Elliott M, Cohen P. The specificities of proteinkinase inhibitors: an update. Biochem J. 2003;371:199-204.
27. Abi-Gerges N, Fischmeister R, Méry P-F. G protein-mediated inhibitoryeffect of a nitric oxide donor on the L-type Ca2- current in rat ventricularmyocytes. J Physiol. 2001;531:117-130.
28. Wei JY, Cohen ED, Genieser HG, Barnstable CJ. Substituted cGMPanalogs can act as selective agonists of the rod photoreceptorcGMP-gated cation channel. J Mol Neurosci. 1998;10:53-64.
29. Francis SH, Bessay EP, Kotera J, Grimes KA, Liu L, Thompson WJ, Corbin JD. Phosphorylation of isolated human phosphodiesterase-5 regulatorydomain induces an apparent conformational change and increasescGMP binding affinity. J Biol Chem. 2002;277:47581-47587.
30. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA. Regulation ofcGMP-specific phosphodiesterase (PDE5) phosphorylation in smoothmuscle cells. J Biol Chem. 2002;277:3310-3317.
31. Kotera J, Grimes KA, Corbin JD, Francis SH. CGMP-dependent proteinkinase protects cGMP from hydrolysis by phosphodiesterase-5. BiochemJ. 2003;372:419-426.
32. Thompson WJ, Appleman MM. Multiple cyclic nucleotide phosphodiesteraseactivities from rat brain. Biochemistry. 1971;10:311-316.
33. Willoughby D, Cooper DM. Organization and Ca2- regulation ofadenylyl cyclases in cAMP microdomains. Physiol Rev. 2007;87:965-1010.
34. Sette C, Conti M. Phosphorylation and activation of a cAMP-specificphosphodiesterase by the cAMP-dependent protein kinase. Involvementof serine 54 in the enzyme activation. J Biol Chem. 1996;271:16526-16534.
35. Degerman E, Belfrage P, Manganiello VC. Structure, localization, andregulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem.1997;272:6823-6826.
36. Piggott LA, Hassell KA, Berkova Z, Morris AP, Silberbach M, Rich TC.Natriuretic peptides and nitric oxide stimulate cGMP synthesis in differentcellular compartments. J Gen Physiol. 2006;128:3-14.
37. Fiedler B, Feil R, Hofmann F, Willenbockel C, Drexler H, Smolenski A, Lohmann SM, Wollert KC. cGMP-dependent protein kinase type Iinhibits TAB1-p38 mitogen-activated protein kinase apoptosis signalingin cardiac myocytes. J Biol Chem. 2006;281:32831-32840.
38. Ferrero R, Rodriguez-Pascual F, Miras-Portugal MT, Torres M. Nitricoxide-sensitive guanylyl cyclase activity inhibition through cyclic GMPdependentdephosphorylation. J Neurochem. 2000;75:2029-2039.
39. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, KoeslingD. Direct activation of PDE5 by cGMP: long-term effects withinNO/cGMP signaling. J Cell Biol. 2003;160:719-727.
40. Wyatt TA, Naftilan AJ, Francis SH, Corbin JD. ANF elicits phosphorylationof the cGMP phosphodiesterase in vascular smooth muscle cells. Am J Physiol Heart Circ Physiol. 1998;43:H448-H455.
41. Kotera J, Fujishige K, Akatsuka H, Imai Y, Yanaka N, Omori K. Novelalternative splice variants of cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem. 1998;273:26982-26990.
42. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N, Tomaselli GF, Hare JM, Kass DA. Cardiac phosphodiesterase 5 (cGMPspecific) modulates-adrenergic signaling in vivo and is down-regulatedin heart failure. FASEB J. 2001;15:1718-1726.
43. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, MergiaE, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, SmithCJ, Kass DA. cGMP catabolism by phosphodiesterase 5A regulatescardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res.2005;96:100-109.
44. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA. Sildenafilinhibits-adrenergic-stimulated cardiac contractility inhumans. Circulation. 2005;112:2642-2649.
45. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA. Chronic inhibition of cyclicGMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med. 2005;11:214-222.
46. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA.PDE5 is converted to an activated state upon cGMP binding to the GAFA domain. EMBO J. 2003;22:469-478.
47. Potter LR, Hunter T. Phosphorylation of the kinase homology domain isessential for activation of the A-type natriuretic peptide receptor. Mol CellBiol. 1998;18:2164-2172.
48. Potter LR. Phosphorylation-dependent regulation of the guanylyl cyclaselinkednatriuretic peptide receptor B: dephosphorylation is a mechanismof desensitization. Biochemistry. 1998;37:2422-2429.
49. Potter LR, Garbers DL. Dephosphorylation of the guanylyl cyclase-Areceptor causes desensitization. J Biol Chem. 1992;267:14531-14534.
50. Chinkers M. Targeting of a distinctive protein-serine phosphatase to theprotein kinase-like domain of the atrial natriuretic peptide receptor. ProcNatl Acad Sci USA. 1994;91:11075-11079.
51. Airhart N, Yang YF, Roberts CT, Silberbach M. Atrial natriuretic peptideinduces natriuretic peptide receptor-cGMP-dependent protein kinaseinteraction. J Biol Chem. 2003;278:38693-38698.
52. Bryan PM, Smirnov D, Smolenski A, Feil S, Feil R, Hofmann F, Lohmann S, Potter LR. A sensitive method for determining the phosphorylationstatus of natriuretic peptide receptors: cGK-Ia does notregulate NPR-A. Biochemistry. 2006;45:1295-1303.
53. Muller B, Stoclet J-C, Lugnier C. Cytosolic and membrane-bound cyclicnucleotide phosphodiesterases from guinea pig cardiac ventricles. EurJ Pharmacol. 1992;225:263-272.
54. Mongillo M, Tocchetti CG, Terrin A, Lissandron V, Cheung YF, Dostmann WR, Pozzan T, Kass DA, Paolocci N, Houslay MD, ZaccoloM. Compartmentalized phosphodiesterase-2 activity blunts-adrenergiccardiac inotropy via an NO/cGMP-dependent pathway. Circ Res. 2006;98:226-234.
55. Honda A, Adams SR, Sawyer CL, Lev-Ram V, Tsien RY, DostmannWR. Spatiotemporal dynamics of guanosine 3-, 5-cyclic monophosphaterevealed by a genetically encoded, fluorescent indicator. Proc Natl AcadSci USA. 2001;98:2437-2442.
56. Nikolaev VO, Gambaryan S, Lohse MJ. Fluorescent sensors for rapidmonitoring of intracellular cGMP. Nat Methods. 2006;3:23-25.
57. Lee CY, Burnett JCJ. Natriuretic peptides and therapeutic applications. Heart Fail Rev. 2007;12:131-142.
58. Tsutamoto T, Kanamori T, Morigami N, Sugimoto Y, Yamaoka O, Kinoshita M. Possibility of downregulation of atrial natriuretic peptidereceptor coupled to guanylate cyclase in peripheral vascular beds ofpatients with chronic severe heart failure. Circulation. 1993;87:70-75. (Pubitemid 23019335)
59. Matsumoto T, Wada A, Tsutamoto T, Omura T, Yokohama H, OhnishiM, Nakae I, Takahashi M, Kinoshita M. Vasorelaxing effects of atrial andbrain natriuretic peptides on coronary circulation in heart failure. Am JPhysiol Heart Circ Physiol. 1999;45:H1935-H1942.